Yang Sai

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Qiaoling Sun, Jinghong Zhou, Zheng Zhang et al. · Cancer Biology & Therapy · 2014 · 146 citations · Full text

Cancer Therapy, Chemoprevention Strategy, Immunology +19

Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450

Yang Sai, Ru-Chun Dai, Tian J. Yang et al. · Xenobiotica · 2000 · 137 citations

Drug Target, Pharmacotherapy, Experimental Pharmacology +17

Discovery of (<i>S</i>)-1-(1-(Imidazo[1,2-<i>a</i>]pyridin-6-yl)ethyl)-6-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-[1,2,3]triazolo[4,5-<i>b</i>]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

Hong Jia, Guangxiu Dai, Jianyang Weng et al. · Journal of Medicinal Chemistry · 2014 · 132 citations · Full text

Compound 28, Pharmacotherapy, Glioma +17

Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs

Yi Gu, Guangji Wang, Jianguo Sun et al. · Food and Chemical Toxicology · 2009 · 125 citations

Ginsenoside Rh2, Pharmacological Study, Anticancer Nutrient +7

Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation

Jing Jin, Yuncui Gan, Huayong Liu et al. · Lung Cancer · 2019 · 94 citations

Dysbiosis, Advanced Lung Disease, Medicine +12